ANDA 62992, held by West-Ward Pharms Int. Doxycycline Hyclate.
As of Nov 16, 2026, ANDA 62992 (Doxycycline Hyclate), held by West-Ward Pharms Int, was first approved by FDA on Feb 16, 1989, with 5 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of Doxycycline for Injection, USP and other antibacterial drugs, Doxycycline for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 16, 1989 | Original application | Approved | None posted |
| Doxycycline HyclateEQ 100MG BASE/VIAL · injectable;injection | Doxycycline Hyclate | Rx |
| Doxycycline HyclateEQ 200MG BASE/VIAL · injectable;injection | Doxycycline Hyclate | Rx |
| Apr 8, 2025 | Supplement 9Labeling · Standard review | Approved | None posted |
| May 5, 2020 | Supplement 2Labeling · Standard review | Approved | None posted |
| May 5, 2020 | Supplement 3Labeling · Standard review | Approved | None posted |
| May 5, 2020 | Supplement 4Labeling · Standard review | Approved | None posted |
| Mar 25, 1996 | Supplement 1Labeling | Approved | None posted |
| Feb 16, 1989 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters